

Claims

- 1           1.     A diagnostic method for determining autoimmune disease or  
2     cancer susceptibility comprising the step of:  
3           haplotyping an individual in a Fas ligand promoter region.
- 1           2.     The method of claim 1 wherein haplotyping occurs at a  
2     polymorph in the Fas ligand promoter region.
- 1           3.     The method of claim 2 wherein said polymorph is active in  
2     binding NF-IL6 transcription factor.
- 1           4.     The method of claim 2 wherein said polymorph is active in  
2     binding TCF/LEF-1.
- 1           5.     The method of claim 2 wherein haplotyping comprises the  
2     polymorph selected from a group consisting of: -844, -756, -478 and -205.
- 1           6.     A method for identifying susceptibility to a disease, said method  
2     comprising:  
3           identifying a first Fas ligand promoter genotype at a nucleotide site of  
4     an individual;  
5           quantifying susceptibility of said individual to the disease; and  
6           comparing susceptibility of said individual to the disease to  
7     susceptibility of a second individual, said second individual having a second

8 Fas ligand promoter genotype, the second Fas ligand promoter genotype being  
9 dissimilar from the first Fas ligand promoter genotype.

1 7. The method of claim 1 wherein said nucleotide site is -844.

1 8. The method of claim 1 wherein said nucleotide site is -756.

1 9. The method of claim 1 wherein said nucleotide site is -478.

1 10. The method of claim 1 wherein said nucleotide site is -205.

1 11. The method of claim 1 wherein said nucleotide site binds NF-  
2 IL6 transcription factor.

1 12. The method of claim 1 wherein said nucleotide site binds  
2 TCF/LEF-1.

1 13. A Fas ligand promoter single nucleotide polymorph.

1 14. The Fas ligand promoter of claim 13 wherein said single  
2 nucleotide polymorph is -844 C/T.

1 15. The Fas ligand promoter of claim 13 wherein said single  
2 nucleotide polymorph is -756 A/G.

1           16. The Fas ligand promoter of claim 13 wherein said single  
2 nucleotide polymorph is -478 C/T.

1           17. The Fas ligand promoter of claim 13 wherein said single  
2 nucleotide polymorph is -205 C/G.

1           18. A diagnostic Fas ligand promoter primer comprising a  
2 nucleotide sequence selected from a group consisting of SEQ ID numbers 1, 2,  
3 3, 4, 5 and 6.

1           19. A test kit for disease susceptibility comprising: reagents for  
2 assaying for a single nucleotide polymorph within a Fas ligand promoter gene  
3 of an individual together with instructions for the use thereof as a diagnostic.

1           20. Use of a single nucleotide polymorph within a Fas ligand  
2 promoter gene of an individual for determining susceptibility of said individual  
3 to a disease.

1           21. The use of claim 19 wherein said disease is selected from a  
2 group consisting of autoimmune disease and non-lymphatic cancer.

1           22. The single nucleotide polymorphism according to claim 13 as  
2 described herein in any of the examples.

09607501 052301  
T0220 T05/0050

1            29.    The Fas promoter of claim 27 wherein said single nucleotide  
2    polymorphism is -95 G/A.

1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

1           30. A test kit for disease susceptibility comprising: reagents for  
2           assaying for a single nucleotide polymorph within a Fas promoter gene of an  
3           individual together with instructions for the use thereof as a diagnostic.

1           31. Use of a single nucleotide polymorph within a Fas promoter  
2           gene of an individual for determining susceptibility of said individual to a  
3           disease.

1           32. A method for identifying susceptibility to a disease, said method  
2           comprising:

3           identifying a first Fas promoter genotype in a nucleotide site of an  
4           individual;

5           quantifying susceptibility of said individual to the disease; and

6           comparing susceptibility of said individual to the disease to  
7           susceptibility of a second individual, said second individual having a second  
8           Fas promoter genotype, the second Fas promoter genotype being dissimilar  
9           from the first Fas promoter genotype.

10